Skip to main navigation Skip to search Skip to main content

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer

Research output: Contribution to journalArticlepeer-review

Abstract

© 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of immediate taxane-based chemohormonal therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.
Original languageEnglish (US)
Article numberCD012816
JournalCochrane Database of Systematic Reviews
Volume2017
Issue number9
DOIs
StatePublished - Sep 30 2017

Bibliographical note

Publisher Copyright:
© 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer'. Together they form a unique fingerprint.

Cite this